An interventional study of Bloodletting acupuncture at the fossa poplitea and Bloodletting acupuncture at the regio glutaea in Back Pain, Low, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.
Among the 59 studies in Low Back Pain with a site in Germany, this one is the 32nd largest by planned enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2023, is one of 31 with no phase, and was the 54th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
University Hospital Augsburg · Sites in Germany
Ages 18+
ZygoFix · Sites in Germany, Italy
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 17 · Phase 4 4
First in 2003; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 128 across the 54 interventional studies, 102 across the 5 observational. Of the 47 that completed or were terminated, 11 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 59 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 9 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 59 studies in Low Back Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of a bloodletting acupuncture at the fossa poplitea in comparison to bloodletting acupuncture at the regio glutaea and a waiting list control group in patients with subacute and chronic non-specific pain low back pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Procedure: Bloodletting acupuncture at the fossa poplitea
Procedure: Bloodletting acupuncture at the regio glutaea
This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
Change from baseline in average pain intensity in previous week
Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).
Time frame: Baseline, 3 weeks
Change from baseline in average pain intensity in previous week
Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).
Time frame: Baseline, 6 weeks
Change from baseline in average pain intensity of the last 24 hours
Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for back pain specific disability
Use of standardized Roland Morris Disability Questionnaire (RMDQ) to assess back pain specific disability. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline in pain bothersomeness in previous week
Bothersomeness in previous week as measured on a 100 mm visual analog scale (0-100).
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for days with pain medication use
Specific self-reported pain medication use
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for health related quality of life
Use of standardized Short Form 36 Health Survey (SF-36). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for pain self-efficacy
Use of standardized Pain Self-Efficacy Questionnaire (PSEQ). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for anxiety and depression
Use of standardized Hospital Anxiety and Depression Scale (HADS). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.
Time frame: Baseline, 3 weeks, 6 weeks
Change from baseline for work productivity
Use standardized Work Productivity and Activity Impairment Questionnaire (WPAI) to assess employment status and productivity. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.
Time frame: Baseline, 3 weeks, 6 weeks
Number of participants with adverse events as a measure of safety and treatment adherence
Identify and assess self reported and unanticipated adverse events over the course of the study as a measure of safety and treatment adherence.
Time frame: 3 weeks, 6 weeks
Treatment adherence
Assess treatment adherence according to attendance during 3 week intervention period.
Time frame: 3 weeks
Treatment expectation: effectiveness of bloodletting acupuncture in reducing low back pain
Assess treatment expectation at baseline, Likert scale (1-very good effectiveness to 5-poor effectiveness)
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.
Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →